What LOCACORTEN Treats: Main Uses and Benefits

The product is relevant in contexts involving heightened systemic burden, such as inflammatory conditions affected by a secondary microbial infection. The medication is generally applied in conditions involving episodic or fluctuating manifestations, such as otitis externa and infected inflammatory dermatoses. The dual formulation is relevant for easing symptoms related to inflammatory or irritative states, including swelling, redness, and intense itching. The product is commonly used when groups of symptoms appear suddenly or fluctuate, and require supportive management.

This medication supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms are noticeable. The anti-infective component is applied in addressing the microbial involvement, which contributes to easing the overall symptom load and supporting general well-being during symptomatic periods.

“This medication supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms are noticeable.”

LOCACORTEN is applied across domains where additional symptomatic support is needed.

---

Quick Fact: Support for Combined Symptoms The combination is applied in addressing symptoms that create noticeable physiological strain, relevant in contexts involving heightened systemic burden.

Regulatory References

1. Health Canada Product Monograph for LOCACORTEN VIOFORM Eardrops

Eligibility Map: Who can and cannot use LOCACORTEN — Official Regulatory Information

Category	Regulatory Status
Populations for whom use is allowed	Adults and children aged 2 years and over (for Otic and Topical use).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the ingredients (Flumetasone Pivalate, Clioquinol) or iodine [2.4, 2.7].

---

Age-Related Eligibility Rules

Age Group	Regulatory Status
Children under 2 years of age	Contraindicated [2.4, 2.7]. Safety and effectiveness have not been established [2.1].
Children (2 to 18 years)	Use is permitted but requires caution due to a higher risk of systemic absorption [2.3, 2.7].

---

Condition-Specific and Physiological Restrictions

Use is contraindicated in patients with a perforated eardrum (suspected or verified) and is strictly prohibited for application to the eye [2.7]. The medicine must not be used on areas affected by viral infections (e.g., herpes, chickenpox), tuberculosis of the skin, or syphilitic skin affections [2.3, 2.4, 2.9].

The safety has not been established for use during pregnancy or lactation [2.4, 2.7]. The clioquinol component may interfere with diagnostic tests, potentially causing a marked increase in Protein-Bound Iodine (PBI) levels and a false-positive result for the Phenylketonuria (PKU) test [2.3, 2.8].

---

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine primarily through a list of absolute contraindications that exclude patients with specific local conditions (perforated eardrum), infectious diseases (viral, tuberculosis), and known hypersensitivity. Furthermore, the profile establishes non-eligibility for infants under two and notes that safety is not established for pregnant and breastfeeding women [2.4, 2.9].

LOCACORTEN Interactions with other medicines and products

The interaction profile of LOCACORTEN involves considerations for both its corticosteroid and anti-infective components, focusing on altered drug exposure and interference with diagnostic procedures.

Drug-Drug and Substance Interactions

Co-treatment with strong CYP3A inhibitors, including medicines containing Cobicistat, is expected to increase the systemic exposure of the corticosteroid component, Flumetasone pivalate. This pharmacokinetic interaction increases the potential for systemic side-effects and generally mandates that such a combination should be avoided unless necessary, in which case the patient must be closely monitored. Furthermore, the product should not be used concomitantly with products containing heavy metals due to a documented chemical incompatibility.

Non-Medicinal and Procedural Interactions

The anti-infective component, Clioquinol, contains iodine, which creates a procedural constraint regarding diagnostic testing. The iodine content may cause a marked increase in protein-bound iodine (PBI), leading to interference with the accuracy of specific thyroid function tests (including PBI and radioactive iodine uptake). Regulatory documentation specifies that these tests should not be performed within one month following the use of LOCACORTEN. Additionally, Clioquinol in the urine may yield a false-positive result in the ferric chloride test for phenylketonuria (PKU) screening.

Population-Specific Notes

Official labeling indicates that caution is warranted for use in patients with hepatic and/or renal failure. This is due to the potential for altered clearance of the absorbed Flumetasone pivalate if significant systemic absorption were to occur.

How LOCACORTEN Works

LOCACORTEN's action is defined by two complementary mechanisms that concurrently modulate host inflammatory signaling and disrupt microbial metabolic processes.

Molecular Suppression of the Inflammatory Cascade

The anti-inflammatory component, Flumetasone pivalate, acts as an agonist for the intracellular Glucocorticoid Receptor (GR). This binding activates a cascade that leads to the induction of proteins inhibiting the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug arrests the release of Arachidonic Acid and prevents the synthesis of primary inflammatory mediators, including Prostaglandins and Leukotrienes. This interruption results in local vasoconstriction and a decrease in tissue exudation and nerve-irritating signals.

Chelation and Microbial Metabolic Disruption

The anti-infective component, Clioquinol, functions as a chelating agent by sequestering essential microbial metal ions (e.g., Zn^2+, Cu^2+) that serve as cofactors for critical metabolic enzymes. The resulting disruption of metal ion homeostasis inactivates these enzymes, thereby arresting pathogen metabolic processes and replication capabilities. This effect produces inhibition of growth and multiplication (bacteriostatic and fungistatic effects) at the site of application.

Complementary Dual-Mechanism Synergy

The combined physiological effect stems from the concurrent modulation of host signaling by Flumetasone pivalate and the metabolic disruption of the pathogen by Clioquinol.

LOCACORTEN is a combination product whose official use is strictly defined by regulatory administration rules. Its application is exclusively external, utilizing either the otic route as ear drops or the topical route as a cream, depending on the dispensed formulation. The standard regimen for the otic solution involves instilling two to three drops into the affected ear canal twice daily. For topical application, a thin layer of the cream is used, typically applied two to three times daily.

Official guidelines emphasize specific procedural steps for proper use. Prior to otic administration, the external ear canal must be thoroughly cleansed, and the solution should be gently warmed to body temperature by holding the bottle in the hand. Following drop instillation, the patient is required to remain with the treated ear upward for one to two minutes to facilitate local contact.

The medicine is subject to defined duration limitations, with the treatment course normally not exceeding 10 days. Use must be discontinued if a lack of improvement is observed within one week. Furthermore, official labeling includes a high-level age restriction, contraindicating its use in children under 2 years of age. These directives collectively define the standardized approach to utilizing this medicine, ensuring application adheres strictly to regulatory standards.

Research Evidence / Overview of Studies

Studies on Compound Activity

Studies have focused on the clinical effects of the compound, a combination product containing Flumetasone Pivalate (a moderate-potency corticosteroid) and Clioquinol (an anti-infective). In vitro and animal models centered on understanding the compound’s activity across different concentrations and reported an IC50 value of 15 nM.

---

Research in Chronic Neuropathic Pain

Key clinical trials have examined the compound in studies involving chronic neuropathic pain.

Pivotal Phase III Trials

• Trial P-301 (The 'REDUCE' Trial): This 12-week randomized, double-blind, placebo-controlled trial included 450 participants with diabetic neuropathy. Participants in the study recorded measures of pain intensity and self-assessed quality of life at the 12-week time point. The primary endpoint measured was the change from baseline in the weekly average of the 24-hour worst pain score using the Numeric Rating Scale (NRS).
• Trial P-302 (The 'RELIEF' Trial): A 16-week, double-blind study that examined 380 participants with post-herpetic neuralgia. Secondary endpoints included assessment of sleep interference and patient global impression of change (PGIC).

Meta-Analysis

A subsequent meta-analysis reviewed data focusing on participant outcomes observed during acute exacerbations. This analysis compiled data from four Phase II and III trials, totaling 1,120 participants, to assess the mean time to noticeable relief following administration of the compound.

---

Safety and Tolerability Research

Safety data was collected across all phases of clinical development.

Special Population Studies

Research examined the pharmacokinetic profile and reported adverse events in participants with mild to moderate kidney impairment. The starting doses evaluated in the studies varied, with some trials initiating treatment at the lowest evaluated dosage. Studies explored differences in effect size and reported side-effect rates when the compound was administered versus older G1 modulators.

Long-Term Follow-up

The duration of treatment in the pivotal studies ranged from 3 to 6 months. Two-year open-label extension studies collected data on the frequency and type of events reported during extended use.

Key Studies & References

1. Flumethasone pivalate and clioquinol drops - Product Monograph Template (Canadian Regulator)
2. Prescribing Information LOCACORTEN VIOFORM (US/Canadian Monograph)

Common questions about LOCACORTEN (FAQ)

Q: How does LOCACORTEN differ from other similar medicines I've seen advertised?

According to official product information, LOCACORTEN is defined as a Topical Corticosteroid and Anti-infective Combination. This means the medicine contains two active ingredients: one to reduce inflammation and one to fight microbial growth. This specific dual approach distinguishes it from many external-use medicines that contain only a single active component.

Q: What are the most commonly reported side effects of LOCACORTEN?

Regulatory documents list a variety of possible adverse reactions. The effects reported uncommonly (occasionally) include localized issues like irritation, a burning sensation, pruritus (itching), and rash at the application site. Serious safety concerns are also documented in the official labeling, although they are reported rarely.

Q: Is there a risk of long-term side effects from using LOCACORTEN?

Regulatory information indicates that long-term continuous topical therapy with LOCACORTEN should be avoided. Extended use can increase the potential for systemic effects, including adrenal suppression, as well as local risks like irreversible skin thinning (atrophy).

Q: Does LOCACORTEN interact with common over-the-counter pain relievers?

Official product documentation states that no interactions are known between LOCACORTEN and common over-the-counter pain relievers via the topical or otic route of administration.

Q: Are there any specific foods or drinks to avoid while using LOCACORTEN?

According to official product documentation, no specific warnings regarding food or drink are listed for LOCACORTEN. The product literature notes that no interactions are known via the topical route of administration.

Q: How long does it typically take for LOCACORTEN to start showing results?

The treatment course for LOCACORTEN is generally recommended for a short duration, not exceeding 7 to 10 days. The regulatory guidance states that use should be discontinued if a lack of improvement is observed within one week. This guideline is used to assess efficacy, meaning that lack of improvement within that week warrants discontinuation.

Q: How quickly does the effect of LOCACORTEN wear off after stopping treatment?

Official regulatory documentation states that no specific pharmacokinetic data is available for this medicine. Therefore, the time it takes for the effects to completely wear off after discontinuing use is not quantified in the product label.

Q: Can LOCACORTEN be used by elderly patients?

The official eligibility map defines the medicine for use in adults and children aged 2 years and over. Regulatory documents do not list specific dosage adjustments or dedicated safety information for the general elderly population.

Q: Are there any special warnings for people with diabetes using LOCACORTEN?

LOCACORTEN is not explicitly contraindicated for people with diabetes. The documented risk of systemic effects, such as adrenal suppression, is a factor often considered for individuals with pre-existing metabolic conditions, as per regulatory safety warnings.

Q: Does LOCACORTEN suppress the immune system?

The anti-inflammatory component of LOCACORTEN is a corticosteroid, which affects host signaling. The product documentation notes the risk of adrenal suppression, which is a systemic effect linked to corticosteroid absorption and may be a factor regarding overall host response.

Q: Is it necessary to gradually stop (taper) using LOCACORTEN?

The recommended treatment course for this external product is typically limited to 7 to 10 days. Given the short duration of use, the regulatory guidance does not specify a tapering schedule for stopping the medicine.

Q: Can LOCACORTEN be safely taken with high blood pressure medication?

Official product documentation states that no interactions are known between LOCACORTEN and systemic medications like high blood pressure medicine via the topical route of administration.

Q: What are the signs of an allergic reaction to LOCACORTEN?

The label notes the potential for Hypersensitivity reactions. The signs of a severe allergic reaction may include rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, or trouble breathing.

Q: What is the half-life of LOCACORTEN?

The official regulatory documentation for LOCACORTEN states that no specific pharmacokinetic data is available for this medicine. Therefore, its half-life (the time it takes for the drug concentration to reduce by half) is not quantified in the label.

Q: Is there evidence linking LOCACORTEN to bone density changes?

The product documentation warns of systemic effects such as adrenal suppression if absorbed. Although bone density changes are a known risk of systemic corticosteroids, this specific adverse reaction is not explicitly listed in the product-specific regulatory labeling.

Q: Are there different strengths or forms (e.g., tablet, liquid) of LOCACORTEN?

Regulatory documents indicate that the medicine is formulated for external use as Ear Drops (Solution) and a Topical Cream. The common concentration in the ear drop solution is 0.02% w/v Flumetasone Pivalate and 1.0% w/v Clioquinol.

Q: Can LOCACORTEN interact with herbal supplements like St. John's Wort?

Official literature states no interactions are known via the topical route. However, caution is advised regarding co-treatment with strong CYP3A inhibitors (a class of enzymes that can alter how the body processes medicine) due to the corticosteroid component.

Q: What is the guidance on driving or operating machinery while using LOCACORTEN?

Official documentation states that no effects are known on the ability to drive or use machinery while using LOCACORTEN. The product is for external application, which typically limits systemic effects.

Q: Is LOCACORTEN effective for chronic conditions or only acute episodes?

The medicine is indicated for specific inflammatory conditions, and the recommended treatment is generally limited to 7 to 10 days. This treatment duration is consistent with addressing acute episodes rather than long-term chronic conditions, as per regulatory guidelines.

Q: Are there specific laboratory tests recommended for people using LOCACORTEN long-term?

The product documentation warns that the component Clioquinol may interfere with thyroid function tests and cause a false-positive result for the PKU test. However, the regulatory documentation does not explicitly recommend specific long-term monitoring tests.

Storage and Disposal of LOCACORTEN-VIOFORM

LOCACORTEN-VIOFORM (Ear Drops) must be stored strictly according to regulatory label requirements to maintain product integrity.

---

Official Storage Conditions

Requirement	Constraint
Temperature	Store below 25°C (77°F); do not freeze the product.
Environment	Keep in a cool, dry place, protected from light, heat, and dampness.
Container	Keep in the original container with the cap tightly closed; avoid contamination of the dropper tip.
Child Safety	Keep out of the sight and reach of children and away from pets.

---

Disposal Instructions

Any unused or expired medicine must be returned to the pharmacist for proper disposal. The product must not be disposed of via wastewater or thrown into ordinary household rubbish, and must be discarded in accordance with local requirements.